GEFTIGET
Description
Gefitinib belongs to a new class of anti cancer drugs called tyrosine-kinase inhibitors which preferentially targets cancer cells unlike the older cancer chemotherapeutic drugs. Gefitinib has shown excellent results in a sub-group of lung cancer patients with EGFR mutation.
Indications:
- As monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from gefitinib
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Gefitinib | 250 mg | IP | Tab. | Bottle | 10s |